데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
1865733-40-9CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.OCOWBUPJEEDYWKD-UHFFFAOYSA-N1865733-40-9DTXSID401027869CHEMBL3989937안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Capmatinib dihydrochloride hydrate is a orally active,reversible MET tyrosine kinase inhibitor that received approval for advanced non-small cell lung cancer(NSCLC) harboring MET exon 14 skipping mutationa. Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase[1-3].
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…